Found: 16
Select item for more details and to access through your institution.
A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
- Published in:
- 2010
- By:
- Publication type:
- journal article
A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [<sup>18</sup>F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease.
- Published in:
- Journal of Alzheimer's Disease, 2010, v. 22, n. 4, p. 1241, doi. 10.3233/JAD-2010-100939
- By:
- Publication type:
- Article
Modeling Alzheimer’s disease progression using the disease system analysis approach
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2012, v. 8, n. 1, p. 39, doi. 10.1016/j.jalz.2010.12.012
- By:
- Publication type:
- Article
Effects of 6-month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild-to-moderate Alzheimer's disease
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Secondary endpoint and responder analyses in a study of rosiglitazone XR in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Safety and tolerability of rosiglitazone XR in a randomised, placebo-controlled study in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's Disease: A <sup>18</sup>F-FDG PET study
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A <sup>18</sup>F-FDG PET study
- Published in:
- 2009
- By:
- Publication type:
- Abstract
O3-04-06: Efficacy and tolerability of SB-742457, a novel 5HT<sub>6</sub> receptor antagonist, in subjects with mild-to-moderate Alzheimer's disease (AD)
- Published in:
- 2008
- By:
- Publication type:
- Abstract
O2-04-08: Long-term safety and tolerability of rosiglitazone XR in Alzheimer’s disease
- Published in:
- 2007
- By:
- Publication type:
- Abstract
P2-397: Safety and tolerability of rosiglitazone (RSG) in patients with mild to moderate Alzheimer’s disease (AD)
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O4-03-07: Efficacy of rosiglitazone (RSG) in patients with mild to moderate Alzheimer’s disease (AD)
- Published in:
- 2006
- By:
- Publication type:
- Abstract
P2-397: Safety and tolerability of rosiglitazone (RSG) in patients with mild to moderate Alzheimer’s disease (AD)
- Published in:
- 2006
- By:
- Publication type:
- Abstract
O4-03-07: Efficacy of rosiglitazone (RSG) in patients with mild to moderate Alzheimer’s disease (AD)
- Published in:
- 2006
- By:
- Publication type:
- Abstract
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study.
- Published in:
- Dementia & Geriatric Cognitive Disorders, 2010, v. 30, n. 2, p. 131, doi. 10.1159/000318845
- By:
- Publication type:
- Article